USPSTF Reaffirms Rec Against Routine Screening for Genital Herpes
(MedPage Today) -- The U.S. Preventive Services Task Force (USPSTF) has reaffirmed a 2016 recommendation against routine serologic screening for genital herpes simplex virus (HSV) in asymptomatic adults and adolescents, including pregnant individuals... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - February 14, 2023 Category: Infectious Diseases Source Type: news
USPSTF Reaffirms Recommendation Against Genital Herpes Screening
TUESDAY, Feb. 14, 2023 -- The U.S. Preventive Services Task Force (USPSTF) recommends against routine screening for genital herpes simplex virus (HSV) among asymptomatic adults and adolescents. This recommendation forms the basis of a final... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 14, 2023 Category: Pharmaceuticals Source Type: news
Anogenital HSV in children: should providers be concerned for sexual abuse? - Keogh A, Goldberg A, Schroeder C, Slingsby B, Hardy E, Michelow I.
OBJECTIVE: Anogenital herpes simplex virus (HSV) is most commonly acquired via sexual transmission although other nonsexual modes of transmission have been proposed. When a child presents with a first-time outbreak of anogenital HSV, providers must conside... (Source: SafetyLit)
Source: SafetyLit - January 26, 2023 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news
Study links viral infections to Alzheimer ’s, Parkinson’s—with many caveats
A massive data mining study has found numerous associations between common viruses like the flu and devastating neurodegenerative disorders such as Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease). The findings expand on previous research linking individual viruses to neurological diseases. But experts caution that the study, which relied on electronic medical records rather than biological samples, merely describes correlations and doesn’t prove causation.
Still, it’s “really exciting,” says Kristen Funk, a neuroimmunologist who studi...
Source: ScienceNOW - January 19, 2023 Category: Science Source Type: news
Angular cheilitis around the mouth could signal a vitamin B deficiency - expert
The condition is often confused for cold sores, a dental hygienist warned. (Source: Daily Express - Health)
Source: Daily Express - Health - January 12, 2023 Category: Consumer Health News Source Type: news
Facial paralysis after intraoral anesthetic injection: A systematic review
Dent Med Probl . 2022 Oct-Dec;59(4):617-627. Abstract Many complications can occur after the injection of local intraoral anesthetics (ILIA) before dental intervention. Facial paralysis (FP) is one of these complications. The purpose of this study was to systematically analyze the association between ILIA and FP. A systematic review was carried out taking into account the methodology of the Cochrane Handbook for Systematic Reviews of Interventions and the PRISMA statement. The search strategy used " Palsy AND Facial " and " Paralysis AND Facial " as search terms. The ScienceDirect, PubMed and Scopus databases were searche...
Source: Dental Technology Blog - January 6, 2023 Category: Dentistry Source Type: news
New TREMFYA ® (guselkumab) Post-Hoc Analysis Reveals Early Efficacy Predicted Longer-Term Efficacy And Sustained Achievement Among A Diverse Active Psoriatic Arthritis Patient Population
SPRING HOUSE, PENNSYLVANIA, November 11, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new post-hoc analysis of the Phase 3 DISCOVER program (DISCOVER-1 and DISCOVER-2) evaluating TREMFYA® (guselkumab) in adult patients with active psoriatic arthritis (PsA), which showed that early skin and enthesitis responsesa,b predicted longer-term clinical response,c including disease remission, at week 52.1 TREMFYA is the first fully human selective interleukin (IL)-23 inhibitor therapy approved in the U.S. for adults with moderate to severe plaque psoriasis (PsO) and adults with active PsA...
Source: Johnson and Johnson - November 11, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
New TREMFYA ® (guselkumab) Post-Hoc Analysis Reveals Active Psoriatic Arthritis Patients With Early Efficacy Had Meaningful Long-Term Improvement in Health-Related Quality of Life
SPRING HOUSE, PENNSYLVANIA, November 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new post-hoc analysis of the Phase 3 DISCOVER-2 study that show early (week 8) clinical improvementsa of most measures (joint and skin disease, enthesitis and dactylitis) in adult patients with active psoriatic arthritis (PsA) treated with TREMFYA® (guselkumab) were associated with meaningful improvements in health-related quality of life (HRQoL) (measured by EQ-5D)b from year one (week 52) through year two (week 100).1 TREMFYA is the first fully human selective interleukin (IL)-23 inhibitor th...
Source: Johnson and Johnson - November 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Viral Shedding Common After First-Episode Genital HSV-1 Infection
MONDAY, Oct. 31, 2022 -- Genital viral shedding is frequent after first-episode genital herpes simplex virus type 1 (HSV-1) infection, particularly among those with primary infection, according to a study published online Oct. 22 in the Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 31, 2022 Category: Pharmaceuticals Source Type: news
New TREMFYA ® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2b QUASAR Induction Study 1 in adults with moderately to severely active ulcerative colitis (UC) with inadequate responses to previous treatments. The data presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting show an overall clinical response rate of approximately 80 percent in patients who were randomized to TREMFYA® (guselkumab).Clinical responsea at weeks 12 or 24 of the study was ultimately achieved by 80.2 percent of patients who w...
Source: Johnson and Johnson - October 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
London scientists find cancer tumours in terminally ill patients are eradicated by herpes virus
An early trial at the Institute for Cancer Research (ICR) in London revealed that a modified version of the herpes simplex virus showed signs of effectiveness. (Source: the Mail online | Health)
Source: the Mail online | Health - September 23, 2022 Category: Consumer Health News Source Type: news
TREMFYA ®▼ (guselkumab) Demonstrates Higher Rates of Complete Skin Clearance with Earlier Treatment in Adults with Moderate to Severe Plaque Psoriasis in Phase 3b GUIDE Study
Beerse, Belgium, 8 September 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data for TREMFYA®▼(guselkumab) from the ongoing Phase 3b GUIDE study, which is designed to understand the impact of early intervention and potential dosing interval flexibility on the long-term disease course in adult patients with moderate to severe plaque psoriasis (Pso). These new data demonstrated that “super responders”a to guselkumab who received every-16-week dosingb maintained disease control (absolute Psoriasis Area and Severity Index [PASI] score <3) at a rate that was non-inferior to ...
Source: Johnson and Johnson - September 8, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Mechanistic Link Between Herpes Virus, Alzheimer's Revealed? Mechanistic Link Between Herpes Virus, Alzheimer's Revealed?
Varicella zoster virus infection may activate dormant herpes simplex virus causing neuroinflammation and accumulation of Alzheimer ' s disease-related proteins, new research suggests.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 16, 2022 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Alzheimer's Retinal Exams; Convicted Neurologist Dies; Another ALS Drug Heads to FDA
(MedPage Today) -- Several different retinal exams are being evaluated as potential ways to screen for Alzheimer's disease. (Scientific American)
Varicella zoster virus may play a role in Alzheimer's by reactivating herpes simplex virus type 1... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - August 16, 2022 Category: Neurology Source Type: news
